For patients with stage III or IV Hodgkin lymphoma, nivolumab with doxorubicin, vinblastine, and dacarbazine (N+AVD) yields ...

An immunotherapy approach to treating advanced Hodgkin lymphoma may drastically increase patients’ chances of survival, ...

A new drug combo recently approved by the Food & Drug Administration can halt lung cancer in its treacherous tracks — for ...

Jazz Pharmaceuticals’ Zepzelca, once on the brink of a market withdrawal, has returned with new trial results showing it ...

Patients with gallbladder cancer and cholangiocarcinoma may benefit from receiving Avastin plus Tarceva versus active ...

Corcept could be significantly undervalued based on long term potential growth and science-based innovation. Find out why ...

For a subset of patients with inoperable or metastatic HR-positive/HER2-negative breast cancer, treatment with datopotamab ...

Long-term results support the use of capmatinib in patients with previously treated or untreated METex14 NSCLC, according to researchers.

Patients with limited-stage SCLC were randomly assigned to receive durvalumab with or without tremelimumab or placebo as ...

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent GlioblastomaCohort A Data ...

Locally advanced cervical cancer remains a substantial source of mortality, particularly in low-resource settings.1 ...

A new combination therapy of lurbinectedin and atezolizumab showed promising results in improving overall survival and ...